Skip to content{"success":true,"data":{"id":"twse-mops-c2dgwm","title":"本公司與某國際製藥公司簽署主服務合約","summary":"1.事實發生日:115/10/08 2.契約或承諾相對人:某國際製藥公司 3.與公司關係:無 4.契約或承諾起迄日期（或解除日期）:115/08/27 5.主要內容（解除者不適用）: (1)本公司與某國際製藥公司簽署主服務合約（Master Services Agreement） ，提供藥械合一之藥物遞送整合解決方案，應用於特定藥物之研究、臨床及開發， 相關服務係用於肺部相關疾病治療。 (2)依合約約定，本公司將就特定藥物之研究、臨床及開發需求，提供包含霧化技 術、藥物遞送整合、法規支援及相關軟硬體等技術服務，並依實際執行之工作內容 取得相應服務收入；後續如有相關開發或臨床試驗需求，雙方將依合約約定另行 確認服務內容及工作範圍。 6.限制條款（解除者不適用）:無 7.承諾事項（解除者不適用）:本公司應依合約約…","canonicalUrl":"https://mops.twse.com.tw/mops/web/t05st01?TYPEK=all&co_id=6934&encodeURIComponent=1&firstin=1&inpuType=co_id&off=1&step=1&year=115&spoke_date=20261008&spoke_time=142534","sourceName":"TWSE Market Observation Post System","sourceUrl":"https://mops.twse.com.tw/mops/web/t05st01","publishedAt":"2026-10-08T06:25:34.000Z","updatedAt":null,"language":"zh-TW","timeZone":"Asia/Taipei","region":"taiwan","country":"TW","market":"Taiwan","topics":["company-announcement","taiwan"],"relatedAssets":["6934"],"importance":"normal","image":null,"imageRights":null,"contentType":"company-announcement","disclosure":"Official company announcement from 心誠鎂; use the filtered MOPS search page to verify the complete filing.","provenance":{"sourceId":"twse-mops","sourceType":"exchange","official":true,"verification":"PRIMARY_SOURCE_METADATA","fetchedAt":"2026-10-08T23:43:09.538Z","stale":true,"archived":true,"classificationMethod":"RULE_BASED"}},"meta":{"generatedAt":"2026-10-08T23:47:15.537Z","providers":[{"id":"jiguang-news-archive","name":"Jiguang Finance source archive","kind":"news","status":"degraded","itemCount":1,"cache":"STALE","fetchedAt":"2026-10-08T23:43:09.538Z","sourceUrl":"https://jiguang.uk/sources.html","message":"Archived publisher metadata; original publication and fetch times retained. Archive availability is not source freshness."}],"stale":true,"apiVersion":"v2"},"error":null}